

**Oxfendazole / Oxyκλοzanide Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.0	14.04.2025	7942511-00008	Date of first issue: 19.03.2021

**SECTION 1. PRODUCT AND COMPANY IDENTIFICATION**

Product name : Oxfendazole / Oxyκλοzanide Formulation

**Manufacturer or supplier's details**

Company name of supplier : MSD  
Address : 126 E. Lincoln Avenue  
Rahway, New Jersey U.S.A. 07065  
Telephone : 908-740-4000  
Emergency telephone : 1-908-423-6000  
E-mail address : EHSDATASTEWARD@msd.com

**Recommended use of the chemical and restrictions on use**

Recommended use : Veterinary medicine  
Restrictions on use : Not applicable

**SECTION 2. HAZARDS IDENTIFICATION****GHS Classification**

Reproductive toxicity : Category 1B  
Specific target organ toxicity : Category 2 (Central nervous system)  
- single exposure (Oral)  
Specific target organ toxicity : Category 2 (Liver, Testis, Brain)  
- repeated exposure

**GHS label elements**

Hazard pictograms :



Signal Word : Danger

Hazard Statements : H360FD May damage fertility. May damage the unborn child.  
H371 May cause damage to organs (Central nervous system) if swallowed.  
H373 May cause damage to organs (Liver, Testis, Brain) through prolonged or repeated exposure.

Precautionary Statements : **Prevention:**  
P201 Obtain special instructions before use.  
P202 Do not handle until all safety precautions have been read and understood.  
P260 Do not breathe dust.  
P264 Wash skin thoroughly after handling.  
P270 Do not eat, drink or smoke when using this product.  
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

**Response:**

## Oxfendazole / Oxyκλοzanide Formulation

Version 4.0      Revision Date: 14.04.2025      SDS Number: 7942511-00008      Date of last issue: 30.09.2023  
Date of first issue: 19.03.2021

P308 + P311 IF exposed or concerned: Call a POISON CENTER/ doctor.

**Storage:**

P405 Store locked up.

**Disposal:**

P501 Dispose of contents/ container to an approved waste disposal plant.

**Other hazards**

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

**SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS**

Substance / Mixture : Mixture

**Components**

Chemical name	CAS-No.	Concentration (% w/w)
Oxyκλοzanide	2277-92-1	>= 30 -< 50
oxfendazole	53716-50-0	>= 20 -< 30
Starch, oxidized	65996-62-5	>= 10 -< 20
Magnesium stearate	557-04-0	>= 1 -< 5

**SECTION 4. FIRST AID MEASURES**

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.
- If inhaled : If inhaled, remove to fresh air.  
Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.  
Remove contaminated clothing and shoes.  
Get medical attention.  
Wash clothing before reuse.  
Thoroughly clean shoes before reuse.
- In case of eye contact : If in eyes, rinse well with water.  
Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention.  
Rinse mouth thoroughly with water.  
Never give anything by mouth to an unconscious person.
- Most important symptoms and effects, both acute and delayed : Contact with dust can cause mechanical irritation or drying of the skin.  
Dust contact with the eyes can lead to mechanical irritation.  
May damage fertility. May damage the unborn child.  
May cause damage to organs if swallowed.  
May cause damage to organs through prolonged or repeated exposure.
- Protection of first-aiders : First Aid responders should pay attention to self-protection,

**Oxfendazole / Oxyclozanide Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.0	14.04.2025	7942511-00008	Date of first issue: 19.03.2021

Notes to physician : and use the recommended personal protective equipment when the potential for exposure exists (see section 8).  
: Treat symptomatically and supportively.

**SECTION 5. FIRE-FIGHTING MEASURES**

Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical

Unsuitable extinguishing media : None known.

Specific hazards during fire fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.  
Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides  
Chlorine compounds  
Nitrogen oxides (NO<sub>x</sub>)  
Metal oxides  
Oxides of phosphorus

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.

Special protective equipment for fire-fighters : In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.

**SECTION 6. ACCIDENTAL RELEASE MEASURES**

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.  
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.  
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).  
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are

**Oxfendazole / Oxytoclozanide Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.0	14.04.2025	7942511-00008	Date of first issue: 19.03.2021

released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

**SECTION 7. HANDLING AND STORAGE**

- |                             |   |  |
|-----------------------------|---|--|
| Technical measures          | : | Static electricity may accumulate and ignite suspended dust causing an explosion.<br>Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.   |
| Local/Total ventilation     | : | If sufficient ventilation is unavailable, use with local exhaust ventilation.  |
| Advice on safe handling     | : | Do not get on skin or clothing.<br>Do not breathe dust.<br>Do not swallow.<br>Avoid contact with eyes.<br>Wash skin thoroughly after handling.<br>Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment<br>Keep container tightly closed.<br>Minimize dust generation and accumulation.<br>Keep container closed when not in use.<br>Keep away from heat and sources of ignition.<br>Take precautionary measures against static discharges.<br>Do not eat, drink or smoke when using this product.<br>Take care to prevent spills, waste and minimize release to the environment. |
| Hygiene measures            | : | If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.<br>When using do not eat, drink or smoke.<br>Wash contaminated clothing before re-use.<br>The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.   |
| Conditions for safe storage | : | Keep in properly labeled containers.<br>Store locked up.<br>Keep tightly closed.<br>Store in accordance with the particular national regulations.  |
| Materials to avoid          | : | Do not store with the following product types:<br>Strong oxidizing agents<br>Self-reactive substances and mixtures<br>Organic peroxides<br>Explosives<br>Gases   |

## Oxfendazole / Oxcyclozanide Formulation

Version 4.0      Revision Date: 14.04.2025      SDS Number: 7942511-00008      Date of last issue: 30.09.2023  
 Date of first issue: 19.03.2021

## SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

## Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Oxcyclozanide	2277-92-1	TWA	0.4 mg/m <sup>3</sup> (OEB 2)	Internal
oxfendazole	53716-50-0	TWA	40 µg/m <sup>3</sup> (OEB 3)	Internal
		Wipe limit	400 µg/100 cm <sup>2</sup>	Internal
Starch, oxidized	65996-62-5	VLE-PPT (inhalable dust)	0.5 mg/m <sup>3</sup>	NOM-010-STPS-2014
		TWA (inhalable dust)	0.5 mg/m <sup>3</sup>	ACGIH
Magnesium stearate	557-04-0	VLE-PPT	10 mg/m <sup>3</sup>	NOM-010-STPS-2014
		TWA (Inhalable particulate matter)	10 mg/m <sup>3</sup>	ACGIH
		TWA (Respirable particulate matter)	3 mg/m <sup>3</sup>	ACGIH

**Engineering measures** : All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.  
 Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).  
 Minimize open handling.

**Personal protective equipment**

**Respiratory protection** : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

**Filter type** : Particulates type

**Hand protection**

**Material** : Chemical-resistant gloves

**Remarks** : Consider double gloving.

**Eye protection** : Wear safety glasses with side shields or goggles.  
 If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.  
 Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

**Skin and body protection** : Work uniform or laboratory coat.

**Oxfendazole / Oxyclozanide Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.0	14.04.2025	7942511-00008	Date of first issue: 19.03.2021

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

**SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES**

Appearance	:	powder
Color	:	white to off-white, light cream, cream
Odor	:	No data available
Odor Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	Not applicable
Evaporation rate	:	Not applicable
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	:	Not applicable
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	Not applicable
Relative vapor density	:	Not applicable
Relative density	:	No data available
Density	:	0.88 g/cm <sup>3</sup>
Solubility(ies)		
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available

## Oxfendazole / Oxytetracycline Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.0	14.04.2025	7942511-00008	Date of first issue: 19.03.2021

Viscosity  
Viscosity, kinematic : Not applicable

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

## SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.  
Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.  
Avoid dust formation.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

## SECTION 11. TOXICOLOGICAL INFORMATION

## Information on likely routes of exposure

Inhalation  
Skin contact  
Ingestion  
Eye contact

## Acute toxicity

Not classified based on available information.

**Product:**

Acute oral toxicity : Acute toxicity estimate: > 5,000 mg/kg  
Method: Calculation method

**Components:****Oxytetracycline:**

Acute oral toxicity : LD50 (Rat): 3,519 mg/kg  
Target Organs: Central nervous system

Acute toxicity (other routes of administration) : LDLo (sheep): 10 mg/kg  
Application Route: Intravenous

**oxfendazole:**

Acute oral toxicity : LD50 (Rat): > 6,000 mg/kg  
LD50 (Dog): 1,600 mg/kg

## Oxfendazole / Oxyclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.0	14.04.2025	7942511-00008	Date of first issue: 19.03.2021

LD50 (sheep): 250 mg/kg

**Magnesium stearate:**

Acute oral toxicity	:	LD50 (Rat): > 2,000 mg/kg Method: OECD Test Guideline 423 Assessment: The substance or mixture has no acute oral toxicity Remarks: Based on data from similar materials
Acute dermal toxicity	:	LD50 (Rabbit): > 2,000 mg/kg Remarks: Based on data from similar materials

**Skin corrosion/irritation**

Not classified based on available information.

**Components:****Oxyclozanide:**

Remarks : Not classified due to lack of data.

**oxfendazole:**

Species	:	Rabbit
Result	:	No skin irritation

**Magnesium stearate:**

Species	:	Rabbit
Result	:	No skin irritation
Remarks	:	Based on data from similar materials

**Serious eye damage/eye irritation**

Not classified based on available information.

**Components:****Oxyclozanide:**

Remarks : Not classified due to lack of data.

**oxfendazole:**

Species	:	Rabbit
Result	:	No eye irritation

**Magnesium stearate:**

Species	:	Rabbit
Result	:	No eye irritation
Remarks	:	Based on data from similar materials

## Oxfendazole / Oxclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.0	14.04.2025	7942511-00008	Date of first issue: 19.03.2021

**Respiratory or skin sensitization****Skin sensitization**

Not classified based on available information.

**Respiratory sensitization**

Not classified based on available information.

**Components:****Oxclozanide:**

Routes of exposure	: Dermal
Remarks	: Not classified due to lack of data.

**Magnesium stearate:**

Test Type	: Maximization Test
Routes of exposure	: Skin contact
Species	: Guinea pig
Method	: OECD Test Guideline 406
Result	: negative
Remarks	: Based on data from similar materials

**Germ cell mutagenicity**

Not classified based on available information.

**Components:****Oxclozanide:**

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES)
	Result: negative
	Test Type: Chromosomal aberration
	Test system: Human lymphocytes
	Result: positive
	Test Type: Mouse Lymphoma
Genotoxicity in vivo	Result: positive
	: Test Type: Micronucleus test
	Species: Mouse
	Application Route: Oral
	Result: negative
	Test Type: unscheduled DNA synthesis assay
Germ cell mutagenicity - Assessment	Species: Rat
	Cell type: Liver cells
	Application Route: Oral
	Result: negative
	: Weight of evidence does not support classification as a germ cell mutagen.

**oxfendazole:**

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES)
-----------------------	--

## Oxfendazole / Oxcyclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.0	14.04.2025	7942511-00008	Date of first issue: 19.03.2021

Genotoxicity in vivo	: Result: negative
	: Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
	: Species: Mouse
	: Application Route: Oral
	: Result: positive

**Magnesium stearate:**

Genotoxicity in vitro	: Test Type: In vitro mammalian cell gene mutation test
	: Result: negative
	: Remarks: Based on data from similar materials
	: Test Type: Chromosome aberration test in vitro
	: Method: OECD Test Guideline 473
	: Result: negative
	: Remarks: Based on data from similar materials
	: Test Type: Bacterial reverse mutation assay (AMES)
	: Result: negative
	: Remarks: Based on data from similar materials

**Carcinogenicity**

Not classified based on available information.

**Components:****Oxcyclozanide:**

Remarks	: Not classified due to lack of data.
---------	---------------------------------------

**oxfendazole:**

Species	: Rat
Application Route	: Oral
Exposure time	: 1 Years
Symptoms	: No adverse effects.
Target Organs	: Liver

Species	: Rat
Application Route	: Oral
Exposure time	: 2 Years
Symptoms	: No adverse effects.
Target Organs	: Liver

**Reproductive toxicity**

May damage fertility. May damage the unborn child.

**Components:****Oxcyclozanide:**

Effects on fertility	: Test Type: Two-generation reproduction toxicity study
	: Species: Rat, male and female
	: Application Route: Oral
	: General Toxicity Parent: NOAEL: 25 - 35 mg/kg body weight

## Oxfendazole / Oxclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.0	14.04.2025	7942511-00008	Date of first issue: 19.03.2021

		<p>Symptoms: Reduced body weight, No effects on embryofetal and postnatal development. Result: No effects on fertility.</p> <p>Test Type: Two-generation reproduction toxicity study Species: Rat Application Route: Oral General Toxicity Parent: LOAEL: 75 - 100 mg/kg body weight Symptoms: Reduced body weight, No effects on embryofetal and postnatal development. Result: No effects on fertility.</p> <p>Test Type: Two-generation reproduction toxicity study Species: Rat Application Route: Oral Early Embryonic Development: LOAEL: 75 - 100 mg/kg body weight Result: No fetotoxicity., No teratogenic effects.</p> <p>Test Type: One-generation reproduction toxicity study Species: Rat Application Route: Oral General Toxicity Parent: LOAEL: 80 - 160 mg/kg body weight Result: No fetotoxicity., No teratogenic effects., No effects on fertility.</p>
Effects on fetal development	:	<p>Test Type: Development Species: Rat Application Route: Oral Developmental Toxicity: NOAEL: 200 mg/kg body weight Result: No fetotoxicity., No teratogenic effects.</p> <p>Test Type: Development Species: Rat Application Route: Oral General Toxicity Maternal: LOAEL: 100 mg/kg body weight Result: No fetotoxicity., No teratogenic effects.</p> <p>Test Type: Development Species: Rabbit Application Route: Oral Developmental Toxicity: NOAEL: 32 mg/kg body weight Result: Fetotoxicity., Skeletal malformations.</p>
Reproductive toxicity - Assessment	:	Suspected of damaging the unborn child.
<b>oxfendazole:</b>		
Effects on fertility	:	<p>Test Type: Fertility/early embryonic development Species: Rat, male Application Route: Oral Fertility: NOAEL: 17 mg/kg body weight Target Organs: Testes Result: Effects on fertility.</p>

## Oxfendazole / Oxytetracycline Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.0	14.04.2025	7942511-00008	Date of first issue: 19.03.2021

	<p>Test Type: Two-generation reproduction toxicity study Species: Rat Application Route: Oral Fertility: NOAEL: 0.9 mg/kg body weight Target Organs: Liver Result: No effects on fertility.</p> <p>Test Type: Fertility Species: Mouse Application Route: Oral Duration of Single Treatment: 1 Months Fertility: NOAEL: 750 mg/kg body weight Target Organs: Testes Result: Effects on fertility.</p>
Effects on fetal development	<p>: Test Type: Embryo-fetal development Species: Rat Application Route: Oral Developmental Toxicity: NOAEL: 10 mg/kg body weight Result: positive, Fetal effects.</p> <p>Test Type: Embryo-fetal development Species: Rat Developmental Toxicity: NOAEL: 10 mg/kg body weight Result: positive, Embryo-fetal toxicity.</p> <p>Test Type: Embryo-fetal development Species: Mouse Application Route: Oral Developmental Toxicity: NOAEL: 108 mg/kg body weight Result: positive, Embryo-fetal toxicity., Fetal abnormalities.</p> <p>Test Type: Embryo-fetal development Species: Rabbit Application Route: Oral Developmental Toxicity: NOAEL: 0.625 mg/kg body weight</p>
Reproductive toxicity - Assessment	: Clear evidence of adverse effects on sexual function and fertility, based on animal experiments., Clear evidence of adverse effects on development, based on animal experiments.
<b>Magnesium stearate:</b>	
Effects on fertility	<p>: Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test Species: Rat Application Route: Ingestion Method: OECD Test Guideline 422 Result: negative Remarks: Based on data from similar materials</p>
Effects on fetal development	<p>: Test Type: Embryo-fetal development Species: Rat Application Route: Ingestion</p>

## Oxfendazole / Oxclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.0	14.04.2025	7942511-00008	Date of first issue: 19.03.2021

Result: negative  
Remarks: Based on data from similar materials

**STOT-single exposure**

May cause damage to organs (Central nervous system) if swallowed.

**Components:****Oxclozanide:**

Routes of exposure	: Oral
Target Organs	: Central nervous system
Assessment	: May cause damage to organs.

**STOT-repeated exposure**

May cause damage to organs (Liver, Testis, Brain) through prolonged or repeated exposure.

**Components:****Oxclozanide:**

Target Organs	: Brain, Liver
Assessment	: May cause damage to organs through prolonged or repeated exposure.

**oxfendazole:**

Routes of exposure	: Oral
Target Organs	: Liver, Testis
Assessment	: May cause damage to organs through prolonged or repeated exposure.

**Repeated dose toxicity****Components:****Oxclozanide:**

Species	: Rat
NOAEL	: 9 mg/kg
LOAEL	: 44.5 mg/kg
Application Route	: Oral
Exposure time	: 3 Months
Target Organs	: Brain, Liver, spleen, Adrenal gland
Symptoms	: Liver effects

Species	: Dog
NOAEL	: 5 mg/kg
LOAEL	: 25 mg/kg
Application Route	: Oral
Exposure time	: 3 Months
Target Organs	: Brain, Liver
Symptoms	: blood effects, alteration in liver enzymes

**oxfendazole:**

Species	: Rat
---------	-------

## Oxfendazole / Oxclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.0	14.04.2025	7942511-00008	Date of first issue: 19.03.2021

NOAEL	: 11 mg/kg
Application Route	: Oral
Exposure time	: 2 Weeks
Target Organs	: Blood, Liver, Testis

Species	: Rat
NOAEL	: 3.8 mg/kg
Application Route	: Oral
Exposure time	: 3 Months
Target Organs	: Liver, Testis

Species	: Mouse
NOAEL	: 750 mg/kg
Application Route	: Oral
Exposure time	: 1 Months
Target Organs	: Liver

Species	: Mouse
NOAEL	: 37.5 mg/kg
Application Route	: Oral
Exposure time	: 3 Months
Target Organs	: Liver

Species	: Dog
NOAEL	: 6 mg/kg
Application Route	: Oral
Exposure time	: 1 Months
Remarks	: No significant adverse effects were reported

Species	: Dog
NOAEL	: 11 mg/kg
Application Route	: Oral
Exposure time	: 2 Weeks
Target Organs	: Lymph nodes, thymus gland

Species	: Dog
NOAEL	: 13.5 mg/kg
Application Route	: Oral
Exposure time	: 12 Months
Target Organs	: Liver

**Starch, oxidized:**

Species	: Rat
NOAEL	: 22,500 mg/kg
Application Route	: Ingestion
Exposure time	: 90 Days

**Magnesium stearate:**

Species	: Rat
NOAEL	: > 100 mg/kg
Application Route	: Ingestion
Exposure time	: 90 Days
Remarks	: Based on data from similar materials

## Oxfendazole / Oxclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.0	14.04.2025	7942511-00008	Date of first issue: 19.03.2021

**Aspiration toxicity**

Not classified based on available information.

**Components:****Oxclozanide:**

|| Not applicable

**Experience with human exposure****Components:****Oxclozanide:**

|| Ingestion : Symptoms: May cause, Gastrointestinal disturbance, Central nervous system depression

**SECTION 12. ECOLOGICAL INFORMATION****Ecotoxicity****Components:****Oxclozanide:**|| Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 0.69 mg/l  
Exposure time: 48 h  
Method: OECD Test Guideline 202**oxfendazole:**|| Toxicity to fish : LC50 (Lepomis macrochirus (Bluegill sunfish)): > 2.7 mg/l  
Exposure time: 96 h  
  
LC50 (Oncorhynchus mykiss (rainbow trout)): > 2.5 mg/l  
Exposure time: 96 h|| Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 0.059 mg/l  
Exposure time: 48 h  
Method: OECD Test Guideline 202|| Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 4 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201|| NOEC (Pseudokirchneriella subcapitata (green algae)): > 4 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201|| Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 0.023 mg/l  
Exposure time: 21 d  
Method: OECD Test Guideline 211

## Oxfendazole / Oxytetracycline Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.0	14.04.2025	7942511-00008	Date of first issue: 19.03.2021

**Magnesium stearate:**

- |   |   |  |
|---|---|--|
| Toxicity to fish                                    | : | LC50 ( <i>Leuciscus idus</i> (Golden orfe)): > 100 mg/l<br>Exposure time: 48 h<br>Method: DIN 38412<br>Remarks: Based on data from similar materials   |
| Toxicity to daphnia and other aquatic invertebrates | : | EL50 ( <i>Daphnia magna</i> (Water flea)): > 1 mg/l<br>Exposure time: 47 h<br>Test substance: Water Accommodated Fraction<br>Method: Directive 67/548/EEC, Annex V, C.2.<br>Remarks: Based on data from similar materials<br>No toxicity at the limit of solubility.   |
| Toxicity to algae/aquatic plants                    | : | EL50 ( <i>Pseudokirchneriella subcapitata</i> (green algae)): > 1 mg/l<br>Exposure time: 72 h<br>Test substance: Water Accommodated Fraction<br>Method: OECD Test Guideline 201<br>Remarks: Based on data from similar materials<br>No toxicity at the limit of solubility.<br><br>NOELR ( <i>Pseudokirchneriella subcapitata</i> (green algae)): > 1 mg/l<br>Exposure time: 72 h<br>Test substance: Water Accommodated Fraction<br>Method: OECD Test Guideline 201<br>Remarks: Based on data from similar materials |
| Toxicity to microorganisms                          | : | EC10 ( <i>Pseudomonas putida</i> ): > 100 mg/l<br>Exposure time: 16 h<br>Test substance: Water Accommodated Fraction<br>Remarks: Based on data from similar materials  |

**Persistence and degradability****Components:****Oxytetracycline:**

- |                    |   |   |
|--------------------|---|---|
| Stability in water | : | Hydrolysis: 50 % (156 d)<br>Method: OECD Test Guideline 111 |
|--------------------|---|---|

**oxfendazole:**

- |                    |   |                         |
|--------------------|---|-------------------------|
| Stability in water | : | Hydrolysis: < 5 % (4 d) |
|--------------------|---|-------------------------|

**Magnesium stearate:**

- |                  |   |  |
|------------------|---|--|
| Biodegradability | : | Result: Not biodegradable<br>Remarks: Based on data from similar materials |
|------------------|---|--|

**Bioaccumulative potential****Components:****Oxytetracycline:**

## Oxfendazole / Oxcyclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.0	14.04.2025	7942511-00008	Date of first issue: 19.03.2021

Partition coefficient: n-octanol/water : log Pow: 3.99  
pH: 7  
Method: OECD Test Guideline 107

**oxfendazole:**

Partition coefficient: n-octanol/water : log Pow: 1.95

**Magnesium stearate:**

Partition coefficient: n-octanol/water : log Pow: > 4

**Mobility in soil****Components:****Oxcyclozanide:**

Distribution among environmental compartments : log Koc: 4.83  
Method: OECD Test Guideline 106

**oxfendazole:**

Distribution among environmental compartments : log Koc: 3.2

**Other adverse effects**

No data available

**SECTION 13. DISPOSAL CONSIDERATIONS****Disposal methods**

Waste from residues : Do not dispose of waste into sewer.  
Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

**SECTION 14. TRANSPORT INFORMATION****International Regulations****UNRTDG**

UN number : UN 3077  
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.  
(oxfendazole, oxcyclozanide)

Class : 9  
Packing group : III  
Labels : 9  
Environmentally hazardous : yes

**IATA-DGR**

UN/ID No. : UN 3077  
Proper shipping name : Environmentally hazardous substance, solid, n.o.s.  
(oxfendazole, Oxcyclozanide)

## Oxfendazole / Oxyclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.0	14.04.2025	7942511-00008	Date of first issue: 19.03.2021

Class	: 9
Packing group	: III
Labels	: Miscellaneous
Packing instruction (cargo aircraft)	: 956
Packing instruction (passenger aircraft)	: 956
Environmentally hazardous	: yes

**IMDG-Code**

UN number	: UN 3077
Proper shipping name	: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (oxfendazole, Oxyclozanide)

Class	: 9
Packing group	: III
Labels	: 9
EmS Code	: F-A, S-F
Marine pollutant	: yes

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**

Not applicable for product as supplied.

**Domestic regulation****NOM-002-SCT**

UN number	: UN 3077
Proper shipping name	: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (oxfendazole, Oxyclozanide)

Class	: 9
Packing group	: III
Labels	: 9

**Special precautions for user**

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

**SECTION 15. REGULATORY INFORMATION****Safety, health and environmental regulations/legislation specific for the substance or mixture**

Federal Law for the control of chemical precursors, essential chemical products and machinery for producing capsules, tablets and pills. : Not applicable

**The ingredients of this product are reported in the following inventories:**

AICS	: not determined
DSL	: not determined
IECSC	: not determined

## Oxfendazole / Oxcyclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.0	14.04.2025	7942511-00008	Date of first issue: 19.03.2021

## SECTION 16. OTHER INFORMATION

Revision Date : 14.04.2025  
Date format : dd.mm.yyyy

**Full text of other abbreviations**

ACGIH : USA. ACGIH Threshold Limit Values (TLV)  
NOM-010-STPS-2014 : Mexico. Norm NOM-010-STPS-2014 on Chemicals Polluting the Work Environment - Identification, Assessment and Control - Appendix 1 Occupational Exposure Limits  
ACGIH / TWA : 8-hour, time-weighted average  
NOM-010-STPS-2014 / VLE- : Time weighted average limit value  
PPT

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

# SAFETY DATA SHEET



## Oxfendazole / Oxytoclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.0	14.04.2025	7942511-00008	Date of first issue: 19.03.2021

---

The information is considered as correct, but not exhaustive, and will be used only as a guide, which is based in the current knowledge of the substance or mixture, and is applicable to proper safety precautions for the product.

MX / Z8